Dr. David E. Martin is the co-founder and Chief Development Officer for DFH Pharma, a privately held pharmaceutical company developing second generation maturation inhibitors for the treatment of HIV-1 infection. Dr. Martin was previously SVP for Drug Development & Regulatory Affairs at Tobira Therapeutics, Inc. where he was responsible for all pre-clinical activities, early clinical development, and regulatory affairs. Immediately prior to Tobira, he was SVP for Drug Development & Regulatory Affairs at Panacos Pharmaceuticals where he was part of the team that discovered bevirimat (a first-in-class maturation inhibitor). Prior to Panacos, Dr. Martin held positions at DuPont Pharmaceuticals, SmithKline Beecham, Pharma Research Corporation and Glaxo. Dr. Martin received his PharmD from the University of Southern California (USC) and completed his Residency in Clinical Pharmacy at the USC School of Pharmacy followed by a Fellowship in Drug Development at The University of North Carolina, Chapel Hill and Glaxo, Inc. He has more than 27 years of experience in the Pharmaceutical Industry where has been responsible for managing 24 discovery/early phase clinical programs in a variety of therapeutic areas: cardiovascular, inflammation, respiratory, and HIV. Dr. Martin has published more than 135 peer-reviewed, scientific publications.
Drug Development & Regulatory Affairs, Clinical Pharmacy, Therapeutics.
